Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer

Journal of Clinical Pathology

Volumn 59, Issue 1, 2006, Pages 40-47

  Branca, M ^a   Giorgi, C ^b   Santini, D ^c   Di Bonito, L ^d   Ciotti, M ^e,f   Benedetto, A ^e,f   Paba, P ^e,f   Costa, S ^c   Bonifacio, D ^d   Di Bonito, P ^b   Accardi, L ^b   Favalli, C ^e,f   Syrjanen K ^g  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Research Division   (Singapore)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN P16INK4A; PROTEIN P53; SURVIVIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOMA IN SITU; CONFIDENCE INTERVAL; DISEASE MARKER; EARLY CANCER; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 30444456078     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.026922     Document Type: Article

References (48)

1. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 64. Papillomaviruses. Lyon: IARC, 1995.
2. Syrjänen K, Syrjänen S. Papillomavirus infections in human pathology. Cnichester: J Wiley & Sons, 2000.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
4. Aubin F, Pretet JL, Mougin C, eds. Papillomavirus humains. Biologie et pathologie tumorale. Paris: Editions TEC & DOC, 2003.
5. Bosch FX, de Sanjose S. Human papillomavirus and cervical cancer-burden and assessment or causality. J Natl Cancer Inst Monogr 2003;31:3-13.
6. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
7. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-42.
8. INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004;23:354-65.
9. Giarre M, Caldeira S, Malanchi I, et al. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. J Virol 2001;75:4705-12.
10. Bequet-Romero M, Lopez-Ocejo O. Angiogenesis modulator expression in culture cell lines positive for HPV-16 oncoproteins. Biochem Biophys Res Commun 2000;277:55-61.
11. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000;19:4611-20.
12. Hernandez P, Merino N, Lopez-Ocejo O, et al. A mouse fibroblast cell model to study human papillomavirus-associated tumorigenesis. Biochem Biophys Res Commun 2000;270:119-24.
13. Smith-McCune K, Zhu YH, Hanahan D, et al. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 1997;57:1294-300.
14. Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001;31:325-48.
15. Kim MH, Seo SS, Song YS, et al. Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol Oncol 2003;90:83-90.
16. Kieser A, Weich HA, Brandner G, et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-9.
17. Smith-McCune KK, Zhu Y, Darragh T. Angiogenesis in histologically benign squamous mucosa is a sensitive marker for nearby cervical intraepithelial neoplasia. Angiogenesis 1998;2:135-42.
18. Kodama J, Seki N, Tokumo K, et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 1999;35:485-9.
19. Fujimoto J, Sakaguchi H, Hirose R, et al. Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer 1999;80:827-33.
20. Obermair A, Bancher-Todesca D, Bilgi S, et al. Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:1212-17.
21. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995;87:1237-45.
22. Tokumo K, Kodama J, Seki N, et al. Different angiogenic pathways in human cervical cancers. Gynecol Oncol 1998;68:38-44.
23. Dobbs SP, Hewett PW, Johnson IR, et al. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer 1997;76:1410-15.
24. Lee JS, Kim HS, Jung JJ, et al. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol 2002;85:469-75.
25. Abulafia O, Triest WE, Sherer DM. Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 1999;72:220-31.
26. Lee JS, Kim HS, Park JT, et al. Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. Anal Quant Cytol Histol 2003;25:303-11.
27. Van Trappen PO, Steele D, Lowe DG, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003;201:544-54.
28. Cheng WF, Chen CA, Lee CN, et al. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 2000;96:721-6.
29. Hashimoto I, Kodama J, Seki N, et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer 2001;85:93-7.
30. Terlikowski S, Lenczewski A, Sulkowska M, et al. Tissue expression of VEGF as a prognostic factor in early cervical squamous cell carcinoma. Folia Histochem Cytobiol 2001;39(suppl 2):112-13.
31. Tjalma W, Weyler J, Weyn B, et al. The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2000;92:251-7.
32. Ueda M, Terai Y, Yamashita Y, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 2002;98:335-43.
33. Lee IJ, Park KR, Lee KK, et al. Prognostic value of vascular endothelial growth factor in stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2002;54:768-79.
34. Branca M, Ciotti M, Santini D, et al.Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 2004;122:902-11.
35. Syrjänen KJ. Immunohistochemistry in assessment of molecular pathogenesis or cervical carcinogenesis. Eur J Gynaecol Oncol 2005;26:5-19.
36. Branca M, Giorgi C, Santini D, et al. Aberrant expression of a novel inhibitor of apoptosis (survivin) is related to grade of cervical intraepithelial neoplasia (CIN), but does not predict virus clearance after cone or prognosis in cervical cancer. Am J Clin Patriot 2005;124:1-9.
37. Branca M, Costa S, Mariani L, et al. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-Pathogen ISS study. Eur J Gynaecol Oncol 2004;25:689-98.
38. Costa S, Terzano P, Santini D, et al. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 2001;80:67-73.
39. Costa S, Terzano P, Santini D, et al. Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 2001;116:729-37.
40. Costa S, Simone PD, Venturoli S, et al. Factors predicting human papillomavirus (HPV) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization. Gynecol Oncol 2003;90:358-65.
41. Bauer HM, Greer CE, Manos M. Determination of genital human papillomavirus infection using consensus PCR. In: Herrington CS, McGee JOD, eds. Diagnostic molecular pathology: a practical approach. Oxford: Oxford University Press, 1992:132-52.
42. Karlsen F, Kalantari M, Jenkins A, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996;34:2095-100.
43. Kleter B, van Doorn U, Scrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-17.
44. Syrjänen KJ. Summary statement on prognostic factors in carcinoma of the uterine cervix. Continuous Medical Education Journal of Gynecological Oncology 2003;8:298-301.
45. Nobbenhuis MAE, Meijer GLM, van den Brule AJC, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796-801.
46. Ueda M, Terai Y, Kumagai K, et al. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol 2001;82:162-6.
47. Fujiwaki R, Hata K, Iida K, et al. Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis. Anticancer Res 2000;20:1317-22.
48. Van Trappen PO, Ryan A, Carroll M, et al. A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 2002;87:537-44.